Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sanofi
Institut Bergonié
Sotio Biotech Inc.
Bristol-Myers Squibb
University of Utah
ImmunityBio, Inc.
ImmunityBio, Inc.
Eastern Cooperative Oncology Group
SWOG Cancer Research Network
Celldex Therapeutics
EMD Serono
Weill Medical College of Cornell University
Fox Chase Cancer Center
Eli Lilly and Company
Rutgers, The State University of New Jersey
Fox Chase Cancer Center
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Louisiana State University Health Sciences Center Shreveport
University of Chicago
Merck Sharp & Dohme LLC
Stanford University
University of Wisconsin, Madison
Western Regional Medical Center
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Pfizer
Daiichi Sankyo
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, Irvine
University of Pittsburgh
Stanford University
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Kansas Medical Center
UNC Lineberger Comprehensive Cancer Center
University of Miami
Washington University School of Medicine
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
SWOG Cancer Research Network
Roswell Park Cancer Institute
Georgetown University
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago